Back Hepatitis C

Hepatitis C

EASL 2015: Another Study Confirms Detrimental Effects of Delaying Hepatitis C Treatment

Deferring antiviral therapy for hepatitis C until a person progresses to advanced liver disease has clear drawbacks including lower treatment effectiveness and an increased risk of clinical events and death, according to a study of U.S. veterans presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.

alt

EASL 2015: Grazoprevir/ Elbasvir Combo Cures 99% of Hepatitis C Patients with Chronic Kidney Disease

Merck's once-daily combination of grazoprevir and elbasvir cured hepatitis C in almost all people with advanced chronic kidney disease, researchers reported at theEuropean Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. The findings from the C-SURFER study are the first evidence that people with chronic kidney disease stand a very high chance of being cured using an interferon-free regimen, and will offer hope to a group of people with hepatitis C until now left behind by recent advances in antiviral treatment.

alt

EASL 2015: Grazoprevir/ Elbasvir Effective for Treatment-Experienced and HIV/HCV Coinfected Patients

The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C virus infection in 12 weeks in some groups of treatment-experienced patients and in HIV/HCV coinfected people, and a 16-week course of treatment with ribavirin was highly effective even for the hardest-to-treat groups of treatment-experienced patients, according to 2 studies presented last week at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna.

alt

EASL 2015: Sofosbuvir-based Treatment Is Safe and Effective in Patients with Advanced Kidney Disease

Direct-acting antiviral therapy for hepatitis C that includes sofosbuvir (Sovaldi) can be used safely and effectively by people with very advanced kidney disease, including patients on dialysis, according to the findings of the HCV-TARGET international cohort study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.

alt

EASL 2015: Advanced Liver Damage Is Common Among People with Undiagnosed Hepatitis C

Around 1 in 5 people with hepatitis C in the U.S. who do not know of their infection may already have advanced liver damage and be in urgent need of treatment, according to a cross-sectional survey of participants in the National Health and Nutritional Examination Survey (NHANES) presented by Prowpanga Udompap at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.

alt

EASL 2015: Patients Who Fail Short Course of Sofosbuvir/Ledipasvir Can Be Cured with 24 Weeks

More than 70% of genotype 1 chronic hepatitis C patients who did not achieve sustained virological response when treated with sofosbuvir/ledipasvir (Harvoni) for 8 or 12 weeks were cured with a subsequent 24-week course of the same 2 drugs, according to a study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.

alt

EASL 2015: Sofosbuvir + Interferon/Ribavirin Effective for Hard-to-Treat Genotype 3 HCV Patients

A throwback regimen of sofosbuvir (Sovaldi), ribavirin, and pegylated interferon taken for 12 weeks cured 93% of patients with hepatitis C virus (HCV) genotype 3 -- substantially more than sofosbuvir plus ribavirin alone taken for 16 or 24 weeks, according to results from the BOSON study presented Saturday at the European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna. Interferon-containing therapy for 3 months was described as "surprisingly well-tolerated."

alt

EASL 2015: Grazoprevir/ Elbasvir Is Highly Effective for Previously Untreated Hepatitis C

A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with hepatitis C virus gentoypes 1, 4, or 6, according to results of the C-EDGE trial presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. However, the study also showed that people with higher baseline HCV viral load and genotype 1a may have a poorer response to this combination, particularly if they have naturally occurring HCV variants that are less sensitive to drugs from the NS5A inhibitor class.

alt

EASL 2015: Sofosbuvir + Daclatasvir + Ribavirin Cures Advanced Cirrhosis and Liver Transplant Patients

An interferon-free regimen of sofosbuvir, daclatasvir, and ribavirin for 12 weeks produced sustained response rates of 83% for hepatitis C patients with advanced liver cirrhosis and 94% for liver transplant recipients, with similar cure rates for those with hard-to-treat HCV genotype 3, according to findings from the ALLY-1 study presented at a late-breaker session at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. More than half of patients with the most severe decompensated cirrhosis achieved sustained response.

alt